Home Crystal structure of methyl 4-{[4-(4-cyanobenzamido)phenyl]amino}benzofuro[2,3-d]pyrimidine-6-carboxylate, C26H17N5O4
Article Open Access

Crystal structure of methyl 4-{[4-(4-cyanobenzamido)phenyl]amino}benzofuro[2,3-d]pyrimidine-6-carboxylate, C26H17N5O4

  • Pei-Xuan Li ORCID logo EMAIL logo , Wei Hui and Qin-Qin Jing
Published/Copyright: February 24, 2022
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 237 Issue 2

Abstract

C46H38N10S2, triclinic, P 1 ‾ (no. 2), a = 8.9297(12) Å, b = 10.9926(15) Å, c = 12.6758(18) Å, α = 104.532(2)°, β = 96.312(2)°, γ = 112.398(2)° V = 1083.8(3) Å3, Z = 2, R gt (F) = 0.0398, wR ref (F2) = 0.1195, T = 296(2) K.

CCDC no.: 1906988

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colorless block
Size: 0.26 × 0.23 × 0.20 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.10 mm−1
Diffractometer, scan mode: Bruker APEX-II, φ and ω
θmax, completeness: 25.0°, >99%
N(hkl)measured, N(hkl)unique, Rint: 7604, 3800, 0.021
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 2865
N(param)refined: 317
Programs: CrysAlisPRO [1], SHELX [2, 3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z Uiso*/Ueq
C1 0.2075 (3) 0.9636 (2) 0.48804 (17) 0.0437 (5)
C2 0.2247 (3) 0.85162 (19) 0.52004 (16) 0.0384 (5)
C3 0.1096 (3) 0.7784 (2) 0.57219 (16) 0.0409 (5)
H3 0.0218 0.8009 0.5863 0.049*
C4 0.1272 (2) 0.6717 (2) 0.60290 (16) 0.0399 (5)
H4 0.0517 0.6233 0.6391 0.048*
C5 0.2565 (2) 0.63591 (19) 0.58034 (15) 0.0338 (4)
C6 0.3689 (2) 0.7075 (2) 0.52555 (16) 0.0398 (5)
H6 0.4535 0.6820 0.5081 0.048*
C7 0.3545 (3) 0.8161 (2) 0.49726 (16) 0.0421 (5)
H7 0.4317 0.8659 0.4628 0.050*
C8 0.2721 (2) 0.5168 (2) 0.60996 (16) 0.0352 (4)
C9 0.2368 (2) 0.41242 (18) 0.76391 (15) 0.0306 (4)
C10 0.2532 (3) 0.4488 (2) 0.87935 (16) 0.0390 (5)
H10 0.2806 0.5402 0.9207 0.047*
C11 0.2291 (3) 0.35066 (19) 0.93276 (16) 0.0386 (5)
H11 0.2416 0.3764 1.0100 0.046*
C12 0.1865 (2) 0.21431 (18) 0.87256 (15) 0.0299 (4)
C13 0.1700 (2) 0.17780 (18) 0.75761 (15) 0.0308 (4)
H13 0.1401 0.0858 0.7165 0.037*
C14 0.1974 (2) 0.27580 (18) 0.70327 (15) 0.0309 (4)
H14 0.1894 0.2505 0.6264 0.037*
C15 0.2079 (2) 0.01272 (18) 0.91373 (14) 0.0285 (4)
C16 0.1607 (2) −0.20249 (19) 0.93002 (15) 0.0363 (5)
H16 0.0955 −0.2762 0.9522 0.044*
C17 0.3759 (2) −0.10197 (19) 0.86383 (14) 0.0312 (4)
C18 0.3500 (2) 0.01644 (18) 0.87303 (14) 0.0273 (4)
C19 0.4905 (2) 0.10971 (18) 0.83988 (14) 0.0289 (4)
C20 0.5858 (2) 0.03535 (19) 0.81361 (15) 0.0338 (4)
C21 0.7340 (2) 0.0853 (2) 0.78159 (17) 0.0419 (5)
H21 0.7941 0.0326 0.7659 0.050*
C22 0.7884 (2) 0.2173 (2) 0.77403 (16) 0.0419 (5)
H22 0.8884 0.2553 0.7532 0.050*
C23 0.6967 (2) 0.2958 (2) 0.79697 (15) 0.0352 (5)
C24 0.5483 (2) 0.24295 (19) 0.83136 (14) 0.0310 (4)
H24 0.4889 0.2960 0.8483 0.037*
C25 0.7596 (2) 0.4320 (2) 0.77734 (16) 0.0407 (5)
C26 0.6936 (3) 0.6120 (2) 0.7482 (2) 0.0580 (6)
H26A 0.8013 0.6784 0.7937 0.087*
H26B 0.6130 0.6483 0.7622 0.087*
H26C 0.6971 0.5940 0.6706 0.087*
N1 0.1922 (3) 1.0516 (2) 0.46162 (16) 0.0588 (5)
N2 0.2515 (2) 0.51604 (15) 0.71448 (13) 0.0361 (4)
H2 0.2468 0.5890 0.7560 0.043*
N3 0.15244 (19) 0.11254 (15) 0.92789 (13) 0.0363 (4)
H3A 0.0904 0.1148 0.9750 0.044*
N4 0.11724 (18) −0.09785 (15) 0.94456 (13) 0.0326 (4)
N5 0.2863 (2) −0.21529 (16) 0.88753 (13) 0.0361 (4)
O1 0.30078 (19) 0.42996 (15) 0.54474 (12) 0.0510 (4)
O2 0.51634 (16) −0.09451 (13) 0.82680 (11) 0.0377 (3)
O3 0.89676 (19) 0.49024 (17) 0.76328 (16) 0.0688 (5)
O4 0.64762 (17) 0.48432 (14) 0.77534 (12) 0.0472 (4)

Source of material

The methyl 4-[(4-aminophenyl)amino]benzofuro[2,3-d] pyrimidine-6-carboxylate 7 (2.0 g, 6.0 mmol), 4-cyanobenzoic acid (1.15 g, 7.8 mmol), HATU (systematic name : 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; 2.96 g, 7.8 mmol) and Et3N (1.2 g, 12.0 mmol) were stirred together in dimethylformamide (15 mL) at room temperature for 7 h. Upon completion of the reaction, the mixture was diluted with saturated sodium carbonate solution (50 mL) and subsequently extracted with dichloromethane. The extracts were combined, washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo. Purification by silica-gel column chromatography provided 2.13 g the desired product. After slowly evaporating the solvents for several days, some light yellow single crystals were obtained.

Experimental details

The structure was solved by direct methods and refined with the SHELX crystallographic software package [1]. The hydrogen atoms were placed at calculated positions and refined as riding atoms.

Comment

Cancer is one of the most health problems in the world; although many classes of drugs were used for the treatment, the needs for safe and effective anticancer compounds are still significant target. Heterocyclic building blocks represent useful scaffolds for applications in medicinal chemistry. To our knowledge, 4-anilinopyrimidine derivatives often have a wide range of biological activities, especially in antitumor drugs [4, 5]. Some of them have been developed as the important prescription antitumor drugs in the market, for example, Pazopanib [6], Ceritinib [7], Brigatinib [8], afatinib [9] and rociletinib [10] are all based on 4-anilinopyrimidine.

The title molecule (see the Figure) has a benzofuro[2,3-d]pyrimidine skeleton, in which all bond lengths and bond angles fall in normal ranges [11]. The dihedral angles between benzofuro[2,3-d]pyrimidine and two phenyl rings are 62.46° and 20.25° respectively. And the two phenyl planes are not coplanar with a dihedral angle of 64.08°. Furthermore, a mass of the intermolecular hydrogen bonds N(3)–H(3A) ⃛ N(4), N(3)–H(3A) ⃛ N(4), C(14)–H(14) ⃛ N(1), C(4)–H(4) ⃛ O(3) and C(11)–H(11) ⃛ O(4) are found in the title structure. It is worth noting that the crystal packing is further stabilized by weak p-p interactions (3.5142 Å). These interactions together with intermolecular hydrogen bond result in the formation of a three-dimensional framework.

Corresponding author: Pei-Xuan Li, College of Safety Science and Engineering, Xi’an University of Science and Technology, Xi’an 710054, China, E-mail:

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Agilent Technologies. CrysAlispro Software system (version 1.171.35.15); Agilent Technologies UK Ltd: Oxford, UK, 2011.Search in Google Scholar

2. Sheldrick, G. M. SHELXTL – Integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Search in Google Scholar

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Abd, E. H. S. R., Lasheen, D. S., Hassan, M. A., Abouzid, K. A. M. Design and synthesis of 4-anilinothieno[2,3-d]pyrimidine-based compounds as dual EGFR/HER-2 inhibitors. Arch. Pharm. 2016, 349, 827–847; https://doi.org/10.1002/ardp.201600197.Search in Google Scholar PubMed

5. Ding, H.-G., Cai, Z.-Q., Hou, L., Hu, Z.-Q., Jin, Z.-S., Xu, D., Cao, H., Meng, M.-M., Xie, Y.-H., Zheng, D.-Q. Synthesis and evaluation of some novel 6-substituted quinazoline derivatives as antitumor agents. J. Chem. Soc. Pakistan 2014, 87, 782–793.Search in Google Scholar

6. Ghith, A., Youssef, K. M., Ismail, N. S. M., Abouzid, K. A. M. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents. Bioorg. Chem. 2019, 83, 111–128; https://doi.org/10.1016/j.bioorg.2018.10.008.Search in Google Scholar PubMed

7. Sailaja, T. G. G., Laxminarayanaa, E., Chary, M. T., Ramesh, M. Synthesis and antibacterial activity of novel 4-{4-(methylamino)thieno[3,2-d]pyrimidin-2-yl}-benzohydrazide derivatives. Russ. J. Gen. Chem. 2017, 87, 1275–1280.10.1134/S1070363217060238Search in Google Scholar

8. Mohan, C., Bhargava, G., Bedi, P. M. S. Thieno[3,2-d] pyrimidin-4-one derivatives as potential antibacterial agents. J. Life Sci. 2009, 2, 97–101; https://doi.org/10.1080/09751270.2009.11885139.Search in Google Scholar

9. Kang, D.-W., Fang, Z.-G., Li, Z.-Y., Huang, B.-S., Zhang, H., Lu, X.-Y., Xu, H.-R., Zhou, Z.-G., Ding, X., Daelemans, D., Clercq, E. D., Pannecouque, C., Zhan, P., Liu, X.-Y. Design, synthesis, and evaluation of thiophene[3,2-d] pyrimidine derivatives as HIV 1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles. J. Med. Chem. 2016, 59, 7991–8007; https://doi.org/10.1021/acs.jmedchem.6b00738.Search in Google Scholar PubMed

10. Kang, D.-W., Fang, Z.-G., Huang, B.-S., Lu, X.-Y., Zhang, H., Xu, H.-R., Huo, Z.-P., Zhou, Z.-G., Yu, Z., Meng, Q., Wu, G.-C., Ding, X., Tian, Y., Daelemans, D., Clercq, E. D., Pannecouque, C., Zhan, P., Liu, X.-Y. Structure-based optimization of thiophene[3,2-d]pyrimidine derivatives as potent HIV 1 non-nucleoside reverse transcriptase inhibitors with improved potency against resistance-associated variants. J. Med. Chem. 2017, 60, 4424–4443; https://doi.org/10.1021/acs.jmedchem.7b00332.Search in Google Scholar PubMed

11. Sheng, J., Liu, Z., Yan, M., Zhang, X., Wang, D., Xu, J., Zhang, E., Zou, Y. Biomass-involved synthesis of N-substituted benzofuro[2,3-d] pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors. Org. Biomol. Chem. 2017, 15, 4971–4977; https://doi.org/10.1039/c7ob00793k.Search in Google Scholar PubMed

Received: 2022-01-13
Accepted: 2022-02-07
Published Online: 2022-02-24
Published in Print: 2022-04-26

© 2022 Pei-Xuan Li et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of {2,2′-{cyclohexane-1,2-diylbis[(azanylylidene)methylylidene]}bis(2,4-dibromophenolato)-κ4 N,N′,O,O′}copper(II) ─ diethylformamide (1/1), C23H23Br4CuN3O3
  4. The crystal structure of 2-(2-methyl-6-phenyl-4H-pyran-4-ylidene)-1H-indene-1,3(2H)-dione, C21H14O3
  5. Crystal structure of bis((1-methylbenzimidazol-2-yl)methyl)amine, C18H19N5
  6. Crystal structure of (E)-N′-(1-(2-hydroxy-4-methoxyphenyl)ethylidene) isonicotinohydrazide, C15H15N3O3
  7. Crystal structure of 2-((4-phenyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetonitrile, C15H11N5S
  8. The crystal structure of 2,2′-((1E,1′E)-hydrazine-1,2-diylidenebis(methaneylylidene))bis(4-chlorophenol), C14H10Cl2N2O2
  9. Dichlorido-{2,6-bis(4,5-dihydro-1H-pyrazol-3-yl)pyridine-κ3 N,N′,N″}zinc(II), C11H9C12N5Zn
  10. The crystal structure of dichlorido-(2-((4-phenyl-2H-1,2,3-triazol-2-yl)methyl)pyridine-κ2N,N′)palladium(II), C14H12Cl2N4Pd
  11. The crystal structure of 1-(N1-benzyl-2-methyl-4-nitro-imidazol-5-yl)-4-(prop-2-yn-1-yl) piperazine, C18H21N5O2
  12. Crystal structure of (μ4-(1,2,4,5-tetra(1,2,4-triazol-1-ylmethyl)-benzene-κ4N:N1:N2:N3)disilver(I) diperchlorate
  13. The crystal structure of 1-(2-bromoethane)-4-amine-3,5-dinitropyrazole, C5H6Br1N5O4
  14. Crystal structure of (E)-1-(4-benzyl-3,5-dioxomorpholin-2-ylidene)ethyl acetate, C15H15N1O5
  15. The crystal structure of poly[diaqua-(μ2-1,2,4,5-tetrakis(1,2,4-triazol-1-ylmethyl)-benzene-κ2N:N′)-bis(μ3-terephthalato-κ3O:O′:O′′)dicadmium(II)], C17H15N6O5Cd
  16. Crystal structure of (E)-N′-(1-(5-chloro-2-hydroxyphenyl) ethylidene)thiophene-2-carbohydrazide, C13H11ClN2O2S
  17. The crystal structure of [(2,2′-bipyridine-k2 N,N)-bis(6-phenylpyridine-2-carboxylato-k2 N,O)cobalt(II)]-monohydrate, C36H26N4O5Co
  18. Crystal structure of (E)-N′-(2-chloro-6-hydroxybenzylidene)-3-hydroxybenzo-hydrazide monohydrate, C14H13ClN2O4
  19. Crystal structure of 1,1′-(methylene)bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-κ2S:S)nickel(II), C42H30N14Ni2S8
  20. Crystal structure of 1,1′-(1,2-ethanediyl)bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-κ2 S:S)nickel(II), C20H14N6NiS4
  21. The crystal structure of 1-methyl-1H-pyrazol-2-ium nitrate, C4H7O3N3
  22. The crystal structure of 4,4′-diselanediylbis(8-(hexyloxy)-3,6-dimethyl-1-(piperidin-1-yl)isoquinoline-7-carbonitrile), C46H60N6O2Se2
  23. The crystal structure of tris(6-methylpyridin-2-yl)phosphine selenide, C18H18N3PSe
  24. The crystal structure of 1,2-bis(2,4-dinitro-1H-imidazol-1-yl)ethane ─ acetone (1/1), C11H12N8O9
  25. Crystal structure of [diaqua[2,2′-(1,2-phenylene)bis(1H-imidazole-4-carboxylato-5-carboxy)-κ4N,N′,O,O′]nickel(II)] tetrahydrate, C16H12N4NiO10·4H2O
  26. The crystal structure of tris(4-methyl-1H-pyrazol-1-yl)methane, C13H16N6
  27. The crystal structure of 5,6-dichloro-2-(quinolin-8-yl)isoindoline-1,3-dione, C17H8Cl2N2O2
  28. Crystal structure of (E)-(2-methoxy-benzylidene)-(4-[1,2,4]triazol-1-yl-phenyl)-amine, C16H14N4O
  29. The crystal structure of (Z)-2-(4-(4-bromophenyl)thiazol-2-yl)-4-(3-hydroxybut-2-enoyl)-5-methyl -1,2-dihydro-3H-pyrazol-3-one – methanol (1/1), C18H18N3O4S
  30. Crystal structure of tetraaqua-tris(nitrato-κ2 O,O′) erbium(III) monohydrate, Er(NO3)3·5H2O, H10ErN3O14
  31. The crystal structure of 1-methyl-2-nitro-1H-imidazole 3-oxide, C4H5N3O3
  32. The crystal structure of 1-methyl-2-nitroimidazole, C4H5N3O2
  33. The crystal structure of 2-carboxyl-4-nitroimidazole monohydrate, C4H5N3O5
  34. Crystal structure of bis[hydrido-hexaphenylcarbodiphosphoran][tetra-trifluoromethyl-(μ-diiodo)-diplatinat]
  35. The crystal structure of poly[μ2-aqua- aqua-(μ3-(E)-2-(4-((2-carbamothioylhydrazineylidene)methyl)phenoxy)acetato-κ3 O:S:S)sodium(I)], C10H14N3O5SNa
  36. The twinned crystal structure of [4,4′-bipyridine]-1,1′-diium hexachloridostannate(IV), C10H10N2SnCl6
  37. The crystal structure of [(2,2′-bipyridine-k2 N,N)-bis(6-phenylpyridine-2-carboxylate-k2 N,O)copper(II)], C34H24N4O4Cu
  38. Crystal structure of trans-1,2-bis(pyridinium-4-yl) ethylene bis(2-carboxy-4-bromobenzoate) – water (1/4), C14H14BrNO6
  39. Crystal structure of poly[diaqua-(μ3-fumarato)-(μ3-maleato)-(μ4-1,2,4,5-tetrakis((1H-1,2,4-triazol-1-yl)methyl)benzene)tetracadmium(II)] dihydrate, C34H32N12O9Cd4
  40. Crystal structure of a second modification of Pachypodol, C18H16O7
  41. Crystal structure of methyl 2-(4-(2-(cyclopentyl-amino)-1-(N-(4-methoxyphenyl)-1-methyl-5-phenyl-1-H-pyrazole-3-carboxamido)-2-oxoethyl)phenyl)acetate, C34H36N4O5
  42. The crystal structure of catena-poly[(m2-4,4′-bipyridine-κ2 N:N)-bis(6-phenylpyridine-2-carboxylato-κ2 N,O) zinc(II)], C34H24N4O4Zn
  43. The crystal structure of hexaquamagnesium(II) (2,4-bis(nitroimino)-6-oxo-1,3,5-triazinane-1,3-diide), C3H15MgN7O12
  44. The crystal structure of 7-Bromo-2-(4-chloro-phenyl)-quinoxaline, C14H9BrClN2
  45. Crystal structure of methyl 4-{[4-(4-cyanobenzamido)phenyl]amino}benzofuro[2,3-d]pyrimidine-6-carboxylate, C26H17N5O4
  46. The crystal structure of (4SR)-7-(3,4-dichlorobenzyl)-4,8,8-trimethyl-7,8-dihydroimidazo[5,1c][1,2,4]triazine-3,6(2H,4H)-dione, C15H16Cl2N4O2
  47. Crystal structure of catena-poly[{μ2-3-carboxy-2,3-bis((4-methylbenzoyl)oxy)propanoato-κ2 O:O′}tris(methanol-κ1 O)lanthanum(III)], C63H63LaO27
https://doi.org/10.1515/ncrs-2022-0013
Creative Commons
BY 4.0

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of {2,2′-{cyclohexane-1,2-diylbis[(azanylylidene)methylylidene]}bis(2,4-dibromophenolato)-κ4 N,N′,O,O′}copper(II) ─ diethylformamide (1/1), C23H23Br4CuN3O3
  4. The crystal structure of 2-(2-methyl-6-phenyl-4H-pyran-4-ylidene)-1H-indene-1,3(2H)-dione, C21H14O3
  5. Crystal structure of bis((1-methylbenzimidazol-2-yl)methyl)amine, C18H19N5
  6. Crystal structure of (E)-N′-(1-(2-hydroxy-4-methoxyphenyl)ethylidene) isonicotinohydrazide, C15H15N3O3
  7. Crystal structure of 2-((4-phenyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetonitrile, C15H11N5S
  8. The crystal structure of 2,2′-((1E,1′E)-hydrazine-1,2-diylidenebis(methaneylylidene))bis(4-chlorophenol), C14H10Cl2N2O2
  9. Dichlorido-{2,6-bis(4,5-dihydro-1H-pyrazol-3-yl)pyridine-κ3 N,N′,N″}zinc(II), C11H9C12N5Zn
  10. The crystal structure of dichlorido-(2-((4-phenyl-2H-1,2,3-triazol-2-yl)methyl)pyridine-κ2N,N′)palladium(II), C14H12Cl2N4Pd
  11. The crystal structure of 1-(N1-benzyl-2-methyl-4-nitro-imidazol-5-yl)-4-(prop-2-yn-1-yl) piperazine, C18H21N5O2
  12. Crystal structure of (μ4-(1,2,4,5-tetra(1,2,4-triazol-1-ylmethyl)-benzene-κ4N:N1:N2:N3)disilver(I) diperchlorate
  13. The crystal structure of 1-(2-bromoethane)-4-amine-3,5-dinitropyrazole, C5H6Br1N5O4
  14. Crystal structure of (E)-1-(4-benzyl-3,5-dioxomorpholin-2-ylidene)ethyl acetate, C15H15N1O5
  15. The crystal structure of poly[diaqua-(μ2-1,2,4,5-tetrakis(1,2,4-triazol-1-ylmethyl)-benzene-κ2N:N′)-bis(μ3-terephthalato-κ3O:O′:O′′)dicadmium(II)], C17H15N6O5Cd
  16. Crystal structure of (E)-N′-(1-(5-chloro-2-hydroxyphenyl) ethylidene)thiophene-2-carbohydrazide, C13H11ClN2O2S
  17. The crystal structure of [(2,2′-bipyridine-k2 N,N)-bis(6-phenylpyridine-2-carboxylato-k2 N,O)cobalt(II)]-monohydrate, C36H26N4O5Co
  18. Crystal structure of (E)-N′-(2-chloro-6-hydroxybenzylidene)-3-hydroxybenzo-hydrazide monohydrate, C14H13ClN2O4
  19. Crystal structure of 1,1′-(methylene)bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-κ2S:S)nickel(II), C42H30N14Ni2S8
  20. Crystal structure of 1,1′-(1,2-ethanediyl)bis(pyridin-1-ium) bis(1,2-dicyanoethene-1,2-dithiolato-κ2 S:S)nickel(II), C20H14N6NiS4
  21. The crystal structure of 1-methyl-1H-pyrazol-2-ium nitrate, C4H7O3N3
  22. The crystal structure of 4,4′-diselanediylbis(8-(hexyloxy)-3,6-dimethyl-1-(piperidin-1-yl)isoquinoline-7-carbonitrile), C46H60N6O2Se2
  23. The crystal structure of tris(6-methylpyridin-2-yl)phosphine selenide, C18H18N3PSe
  24. The crystal structure of 1,2-bis(2,4-dinitro-1H-imidazol-1-yl)ethane ─ acetone (1/1), C11H12N8O9
  25. Crystal structure of [diaqua[2,2′-(1,2-phenylene)bis(1H-imidazole-4-carboxylato-5-carboxy)-κ4N,N′,O,O′]nickel(II)] tetrahydrate, C16H12N4NiO10·4H2O
  26. The crystal structure of tris(4-methyl-1H-pyrazol-1-yl)methane, C13H16N6
  27. The crystal structure of 5,6-dichloro-2-(quinolin-8-yl)isoindoline-1,3-dione, C17H8Cl2N2O2
  28. Crystal structure of (E)-(2-methoxy-benzylidene)-(4-[1,2,4]triazol-1-yl-phenyl)-amine, C16H14N4O
  29. The crystal structure of (Z)-2-(4-(4-bromophenyl)thiazol-2-yl)-4-(3-hydroxybut-2-enoyl)-5-methyl -1,2-dihydro-3H-pyrazol-3-one – methanol (1/1), C18H18N3O4S
  30. Crystal structure of tetraaqua-tris(nitrato-κ2 O,O′) erbium(III) monohydrate, Er(NO3)3·5H2O, H10ErN3O14
  31. The crystal structure of 1-methyl-2-nitro-1H-imidazole 3-oxide, C4H5N3O3
  32. The crystal structure of 1-methyl-2-nitroimidazole, C4H5N3O2
  33. The crystal structure of 2-carboxyl-4-nitroimidazole monohydrate, C4H5N3O5
  34. Crystal structure of bis[hydrido-hexaphenylcarbodiphosphoran][tetra-trifluoromethyl-(μ-diiodo)-diplatinat]
  35. The crystal structure of poly[μ2-aqua- aqua-(μ3-(E)-2-(4-((2-carbamothioylhydrazineylidene)methyl)phenoxy)acetato-κ3 O:S:S)sodium(I)], C10H14N3O5SNa
  36. The twinned crystal structure of [4,4′-bipyridine]-1,1′-diium hexachloridostannate(IV), C10H10N2SnCl6
  37. The crystal structure of [(2,2′-bipyridine-k2 N,N)-bis(6-phenylpyridine-2-carboxylate-k2 N,O)copper(II)], C34H24N4O4Cu
  38. Crystal structure of trans-1,2-bis(pyridinium-4-yl) ethylene bis(2-carboxy-4-bromobenzoate) – water (1/4), C14H14BrNO6
  39. Crystal structure of poly[diaqua-(μ3-fumarato)-(μ3-maleato)-(μ4-1,2,4,5-tetrakis((1H-1,2,4-triazol-1-yl)methyl)benzene)tetracadmium(II)] dihydrate, C34H32N12O9Cd4
  40. Crystal structure of a second modification of Pachypodol, C18H16O7
  41. Crystal structure of methyl 2-(4-(2-(cyclopentyl-amino)-1-(N-(4-methoxyphenyl)-1-methyl-5-phenyl-1-H-pyrazole-3-carboxamido)-2-oxoethyl)phenyl)acetate, C34H36N4O5
  42. The crystal structure of catena-poly[(m2-4,4′-bipyridine-κ2 N:N)-bis(6-phenylpyridine-2-carboxylato-κ2 N,O) zinc(II)], C34H24N4O4Zn
  43. The crystal structure of hexaquamagnesium(II) (2,4-bis(nitroimino)-6-oxo-1,3,5-triazinane-1,3-diide), C3H15MgN7O12
  44. The crystal structure of 7-Bromo-2-(4-chloro-phenyl)-quinoxaline, C14H9BrClN2
  45. Crystal structure of methyl 4-{[4-(4-cyanobenzamido)phenyl]amino}benzofuro[2,3-d]pyrimidine-6-carboxylate, C26H17N5O4
  46. The crystal structure of (4SR)-7-(3,4-dichlorobenzyl)-4,8,8-trimethyl-7,8-dihydroimidazo[5,1c][1,2,4]triazine-3,6(2H,4H)-dione, C15H16Cl2N4O2
  47. Crystal structure of catena-poly[{μ2-3-carboxy-2,3-bis((4-methylbenzoyl)oxy)propanoato-κ2 O:O′}tris(methanol-κ1 O)lanthanum(III)], C63H63LaO27
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 10.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2022-0013/html
Scroll to top button